Patents Represented by Attorney Marc A. Began
-
Patent number: 6855129Abstract: The invention relates to a safety needle assembly for injecting a fluid into a human body comprising a cylindrical housing with a bottom surface supporting a needle cannula and a shield telescopically movable relative to the housing. A spring located within the housing urges the shield in a distal needle covering direction and a locking member also provided inside the housing moves simultaneously with the shield during injection and automatically locks the shield in a position where the sharp end of the needle cannula is concealed thereby irreversible immobilizing the safety needle assembly.Type: GrantFiled: November 29, 2002Date of Patent: February 15, 2005Assignee: Novo Nordisk A/SInventors: Karsten Jensen, Niels Nymark
-
Patent number: 6818738Abstract: Disclosed is a method of preparing zinc free rapid acting insulin analogue. In one embodiment insulin crystals are prepared by providing a solution of an analogue having a pH between 7 and 9.5. The solution is mixed with a salt of an alkali metal or salt and formed crystals are recovered.Type: GrantFiled: May 20, 2002Date of Patent: November 16, 2004Assignee: Novo Nordisk A/SInventor: Svend Havelund
-
Patent number: 6796970Abstract: A dose setting device for a delivery system has a piston rod (6, 9) which successively presses a piston (2) into a cylinder ampoule (1). Doses are set by rotating a second part (9) of the piston rod (6, 9) in relation to a first part (6). The two parts are connected by mating threads so that the total length of the piston rod (6, 9) is increased proportional to the angle of rotation, and a point (18) on the second part is moved away from a stop position fixed in relation to a housing (5) The set dose is delivered when the point (18) is moved back to the stop position. The first part (6) can be axially displaced but not rotated in the housing (5), and the second part (9) can both rotate and be axially displaced. The first part (6) is maintained in abutment with the piston (2) and the second part (9) is coupled to be rotated by a dose setting wheel (20).Type: GrantFiled: June 4, 1998Date of Patent: September 28, 2004Assignee: Novo Nordisk A/SInventors: Lars Peter Klitmose, Henrik Andersen, Preben Broskov Nielsen, John Thrane Hansen
-
Patent number: 6786246Abstract: An apparatus for filling a cartridge with a liquid comprises, a platform on which the cartridge is supported and which can be lifted relative to a stationary filling needle (5) so that this filling needle is moved into the cartridge (6), a pump (1) feeding liquid through the filling needle (5) into the cartridge (6), a sensor head (10) from which a beam of light is sent from one side of the cartridge to the other along a path immediately over an upper edge of the cartridge (6), and a reflector (11) reflecting the light beam back to the sensor head (10), which is connected to a sensor box (12) which produces a signal stopping the pump (1) and causing the needle (5) to be drawn out of the cartridge (6) when this cartridge is full and the liquid forms a droplet over the opening of the cartridge, which droplet deflects the light beam.Type: GrantFiled: November 14, 2003Date of Patent: September 7, 2004Assignee: Novo Nordisk A/SInventors: Rene Ohms, Flemming S. J. Manique, Preben Kobbero
-
Patent number: 6786890Abstract: A linear actuator comprising a first member (1) and a second member (2) provided with internal threads (6,8) cut in opposite directions and an intermediary member (3) engaged with and being axially displaceable in relation to the first and second members (1,2), via external threads (11,12) that are complementary to the threads (6,8) provided on the first and second members (1,2). The linear actuator furthermore comprises a sheath (4) stretching across the intermediary member (3), which sheath (4) is inrotatably, but longitudinally slidably arranged in relation to the first and second members (1,2). The linear actuator also comprises a driving rod (5) that is inrotatably, but longitudinally slidably arranged within the intermediary member (3). A medical delivery device provided with such a linear actuator is also provided.Type: GrantFiled: January 22, 2003Date of Patent: September 7, 2004Assignee: Novo Nordisk A/SInventors: Jan Harald Preuthun, Soren Henrik Ljunggreen
-
Patent number: 6777207Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 Å.Type: GrantFiled: June 28, 2001Date of Patent: August 17, 2004Assignee: Novo Nordisk A/SInventors: Thomas Børglum Kjeldsen, Svend Ludvigsen
-
Patent number: 6755810Abstract: The present invention relates to a transfer device for transferring medicament from a medicament container to a syringe with a needle. The transfer device is arranged for transferring accurate dosages of insulin, growth hormone or other medicaments. The accuracy is ensured by the device comprising means for mounting a syringe to the device, the needle piercing a sealing of the device. Opposite the sealing a piston is arranged, said piston being non-releasable engaged with the piston driver during transfer of the medicament. Thereby the piston is not erroneously drawn from the piston driver, which would otherwise lead to incorrect dosing. Furthermore, the device comprises dosing means including the piston driver.Type: GrantFiled: September 20, 2001Date of Patent: June 29, 2004Assignee: Novo Nordisk A/SInventors: Thomas Buch-Rasmussen, Jens-Ulrik Poulsen, Henrik Ljunggreen
-
Patent number: 6726661Abstract: Described is an electronic injection device wherein an electronic circuit is designed to work in two alternative modes: an air shot mode and a dose injection mode. When working in the air shot mode a small predetermined air shot dose is pressed out from the ampule when the injection button is actuated. When working in the injection mode, a dose set by operation of the dose setting means is injected by operation of the injection button. The electronic injection device is normally working in the air shot mode but shifts to work in the dose injection mode when it receives a signal indicating that the dose setting means has been operated. The circuit returns to its air shot mode when receiving a signal indicating that the set dose has been injected. This signal can originate either from a switch indicating that the protection cap is mounted or from a switch indicating that the injection button has been pressed.Type: GrantFiled: December 10, 2002Date of Patent: April 27, 2004Assignee: Novo Nordisk A/SInventors: Jens Munk, Denmark Denmark Aasmul, Henrik Ljunggreen, Lars Hofmann Christensen
-
Patent number: 6716198Abstract: An injection device for injecting set doses from an ampoule (2) mounted in the device, which doses are set by operation of a dose setting button (7) by which operation elastic torsion rods (14) positioned parallel with the longitudinal axis of the device are twisted. By the dose setting a torque is transmitted from the dose setting button (7) to the rods (14) through gear transmissions comprising a toothing (11) carried by a tubular (8) part coupled to the dose setting button (7) to rotate with this button. The toothing (11) engages pinions (13) fixed to the proximal ends of the torsion rods (14), which are made from a super elastic material, which can stand a deformation larger than 2% without being permanently deformed.Type: GrantFiled: May 11, 2001Date of Patent: April 6, 2004Assignee: Novo Nordisk A/SInventor: Andre Larsen
-
Patent number: 6706744Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.Type: GrantFiled: November 16, 2001Date of Patent: March 16, 2004Assignee: Novo Nordisk A/SInventors: Peter Madsen, Jesper Lau, Anthony Ling
-
Patent number: 6680091Abstract: A medicament container for storing a liquid medicament, such as insulin, comprises a wall with at least two opposite portions made of a polymer material having a light transmission at 400 nm of at least 25%, a glass transition temperature above 50° C., and a density of 0.95 g/cm3 or more. The polymer material comprises at least 70% by weight of a copolymer material composed of aliphatic cyclic or bicyclic hydrocarbons with 5 to 7 membered ring or rings and ethylene or propylene. The container is substantially inert to the medicament and, because it is either transparent or at least includes at least two opposed transparent portions, it is possible visually to inspect the contents of the container to make sure that the medicament has not crystalized or polymerized. The walls of the container provide a good barrier against m-cresol/phenol/benzyl alcohol preservatives and water.Type: GrantFiled: December 16, 1997Date of Patent: January 20, 2004Assignee: Novo Nordisk A/SInventors: Thomas Buch-Rasmussen, Patric Jannasch, Erling Bonne Jørgensen
-
Patent number: 6677358Abstract: The present invention discloses a regimen for the treatment of type 2 diabetes, in which the endogenous secretion of insulin is stimulated in connection with meals, by administering a short-acting, oral hypoglycemic agent. Also, the present invention discloses a method of achieving improvement in glycemic control by combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.Type: GrantFiled: December 13, 1999Date of Patent: January 13, 2004Assignee: Novo Nordisk A/SInventor: Peter Giørtz Müller
-
Patent number: 6669090Abstract: The invention relates to: A method of providing an electronically readable item of information (725) on a medication cartridge (70). The invention further relates to a cartridge (70) containing an electronically readable item of information (725), a support (75) for reading the information (725) on the cartridge (70), a medication delivery device adapted to use a cartridge (70) and a support (75) according to the invention and a label (72) containing an electronically readable item of information (725). The object of the present invention is to provide an alternative method of generating an electronically readable item of information on a cartridge which method is simple and improves safety in reading. The problem is solved in that said item of information is redundantly provided (725, 726). The invention may e.g. be used in connection with medication delivery devices for self-treatment of a disease, e.g. diabetes.Type: GrantFiled: August 9, 2001Date of Patent: December 30, 2003Assignee: Novo Nordick A/SInventor: Michael Eilersen
-
Patent number: 6663602Abstract: An injection device for injection of set does of medicine from a cartridge has a nut that is screwed up along a threaded piston rod during a dose setting operation. The nut is screwed along the piston rod by rotating a dose setting drum. An injection button is coupled to the piston rod with a gear wheel transmission. Axial movement of the injection button causes a corresponding axial movement of the piston rod until the nut engages an abutment in the housing.Type: GrantFiled: June 14, 2001Date of Patent: December 16, 2003Assignee: Novo Nordisk A/SInventor: Claus Schmidt Møller
-
Patent number: 6660197Abstract: The present invention relates to a method and a system for producing an elongated drug formulation being suitable for being injected through the skin of a patient with-out the use of a needle or a cannula. The drug formulation is produced by compressing a drug granulate in cavity of a system comprising a roller and a surface, wherein the roller roles over the surface thereby comprising the granulate to the formulation.Type: GrantFiled: October 12, 2000Date of Patent: December 9, 2003Assignee: Novo Nordisk A/SInventors: Thomas Buch-Rasmussen, Søren Aasmul, James M. Flink, Philip Hansen, Claus Juul-Mortensen, Jens-Ulrik Poulsen
-
Patent number: 6656114Abstract: A method of self treating a disease, such as diabetes, includes collecting in one or more databases data representing values of parameters that related to the self treatment. The data is processed to provide a plurality of alternate choices between two or more actions that may be taken and a corresponding value for each action is calculated. A computerized system may be employed to perform the above method and the system may include a computer readable medium for executing the method.Type: GrantFiled: October 30, 2000Date of Patent: December 2, 2003Assignee: Novo Noadisk A/SInventors: Jens Ulrik Poulsen, Lars Hofmann Christensen, Søren Aasmul
-
Patent number: 6653492Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.Type: GrantFiled: May 1, 2002Date of Patent: November 25, 2003Assignee: Novo Nordick A/SInventor: Peter Faarup
-
Patent number: 6649641Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.Type: GrantFiled: November 16, 2001Date of Patent: November 18, 2003Assignee: Novo Nordisk A/SInventors: Carsten Behrens, Jesper Lau, Peter Madsen
-
Patent number: 6645953Abstract: Sterol derivative compounds, structurally related to natural compounds which can be extracted from bull testes and from human follicular fluid, useful for regulating meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives.Type: GrantFiled: June 11, 2001Date of Patent: November 11, 2003Assignee: Novo Nordisk A/SInventors: Frederik Christian Gronvald, Peter Faarup, Erling Guddal
-
Patent number: 6639515Abstract: A method for clinical surveillance of a treatment group and an other group involves defining an adverse event, possible a serious adverse event, noting each occurrence of the adverse events, and, starting at zero, calculating a cumulative sum of the adverse events by updating the cumulative sum each time a further adverse event is reported and, when the adverse event is in the treatment group, adding 1 to the cumulative sum, and, when the adverse event is in the other group, adding 0 to the cumulative sum. This invention also involves subtracting a chosen quantity K from the cumulative sum, comparing the cumulative sum to a predetermined alarm limit, determining when the cumulative sum reaches at least the predetermined alarm limit, and indicating the predetermined alarm limit has been reached.Type: GrantFiled: October 11, 2001Date of Patent: October 28, 2003Assignee: Novo Nordisk A/SInventor: Philip Hougaard